| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Total other income (expense), net | 2,480 | 2,859 | 2,012 | |
| Net income (loss) | -8,498 | -10,561 | 56,542 | |
| Unrealized gain (loss) on investments, net | 167 | -6 | -43 | |
| Comprehensive income (loss) | -8,331 | -10,567 | 56,499 | |
| Net income (loss) per share basic (in dollars per share) | -0.15 | -0.19 | 1 | |
| Net income (loss) per share, diluted (in dollars per share) | -0.15 | -0.19 | 0.98 | |
| Weighted average common shares outstanding, basic (in shares) | 56,929,103 | 56,803,450 | 56,663,798 | |
| Weighted average common shares outstanding, diluted (in shares) | 56,929,103 | 56,803,450 | 57,673,099 | |
Black Diamond Therapeutics, Inc. (BDTX)
Black Diamond Therapeutics, Inc. (BDTX)